Navigation Links
Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
Date:10/30/2007

- Pfizer-funded Screening Agreement Fuels Discovery of Novel Compounds,

Complements Clinical Development Initiatives with PF-3512676 -

WELLESLEY, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY), a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics(TM), announced today that Pfizer Inc, its global collaborator in the area of cancer, has nominated a second TLR9 agonist compound discovered by Coley for future clinical development against cancers. This second generation drug candidate is expected to complement Pfizer's ongoing clinical programs for PF-3512676, Coley's lead therapeutic TLR9 agonist drug candidate, for the treatment of cancer.

"Our ability to discover and develop a variety of pharmacologically unique TLR9 agonist compounds demonstrates our dexterity in drug development, as well as the breadth of our TLR Therapeutics technology platform," stated Robert L. Bratzler, Ph.D., President and Chief Executive Officer for Coley Pharmaceutical Group. "Pfizer's selection of this new development candidate is a strong testament to the potential of targeting the TLR9 pathway and reflects Pfizer's commitment to discovering and advancing TLR Therapeutic candidates capable of stimulating the immune system to combat cancer."

The new development candidate was discovered by Coley under the two companies' strategic agreement in which Pfizer funds the discovery and development of potential next-generation TLR9 agonists for cancers, including cancer vaccines. Pfizer has exclusive rights to two novel compounds discovered under this agreement, while Coley retains the rights to all other molecules. To date, C
'/>"/>

SOURCE Coley Pharmaceutical Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes ... JIN Co., Ltd. will launch JINS MEME "ACADEMIC PACK" ... yen or $5,000 (without tax /including two pairs of JINS ... a dedicated solution of "JINS MEME" to academic researchers, and ... generated by electrooculography and six-axis sensors without API. (*Physiological data ...
(Date:11/26/2014)... SAN DIEGO , Nov. 26, 2014  Aethlon ... into a definitive agreement to raise approximately $3.3 million ... is being made by one institutional healthcare focused investor. Each ... one-fifth of a common share purchase warrant. Each whole ... at a price of $0.30 for a period of ...
(Date:11/26/2014)... Nov. 26, 2014  Genomic Health, Inc. (Nasdaq: ... Chairman, Chief Executive Officer and President, will participate in ... at The New York Palace Hotel in ... 11:30 am Eastern Time (ET). To access ... call, go to the  Investor Relations  section of the ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3
... 4, 2010 /PRNewswire / -- Streamline Health ... provider of document workflow solutions for hospitals, today announced ... delivery systems in the United States, will implement Streamline ... The solution provides an automated ...
... Syringe Locking-Device Technology at HealthAchieve Conference -- JERUSALEM, November 4, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are ...
Cached Medicine Technology:Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions 2Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions 3Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions 4Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 2Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 3Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 4Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 5Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 6Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 7Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 8
(Date:11/27/2014)... PA (PRWEB) November 27, 2014 ... volunteer Aria Health employees, prepared and donated 200 ... the Lutheran Settlement House , a non-profit, community-based ... families living in Philadelphia. The dinners were assembled ... House Senior Center, and distributed to vulnerable low ...
(Date:11/27/2014)... The Little Gym, we know that being active provides ... a recent study confirmed that regular physical activity can ... Pediatrics found that “Promoting physical activity that involves ... may be important not only for health, but also ... of children; those that were engaging in regular physical ...
(Date:11/27/2014)... Delhi, India (PRWEB) November 27, 2014 ... has announced a search engine optimization service just ... small businesses or start-ups cannot afford costly search ... this service package, keeping their affordablity and requirements ... the service cost, but it has not compromised ...
(Date:11/27/2014)... California (PRWEB) November 27, 2014 The ... You An Up-Close Look At This Year’s Entries | ... An All-Inclusive Stay For Two At Their Resort, Pure ... Times events or L.A.-based Hempcon, The Emerald Cup is ... county fair draws much of California’s original cannabis industry." ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 VeloReality Inc. ... six new Real Life Videos (RLVs) of world-famous velo courses ... Trainer, as well as other popular indoor velo trainers. Two ... available worldwide before the end of November -- in ... the total number of rides in the VeloReality collection to ...
Breaking Medicine News(10 mins):Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 2Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 3Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 4Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3
... has released its global status report on alcohol and ... the discussion in the report of the serious health ... which contributes to accidents, many diseases, and premature deaths. ... that the report was limited almost exclusively to abusive ...
... News) -- The immune systems of people with contact allergies ... including breast and brain cancers, new research suggests. Contact ... metals such as nickel. In the new study, researchers ... contact allergies between 1984 and 2008. About one-third (35 percent) ...
... Research to be presented at the upcoming annual ... Behavior (SSIB), the foremost society for research into all ... some antipsychotic drugs can promote overeating, weight gain, and ... by the FDA for the treatment of schizophrenia and ...
... A new method for scoring the severity of illness ... their outcomes, according to researchers at the University of ... in the early online version of Resuscitation, ... out the potential for a patient,s recovery. ...
... , MONDAY, July 11 (HealthDay News) -- Obstructive ... during sleep, plays a role in blood vessel abnormalities ... conditions, a new study suggests. About 15 ... apnea, according to the American Heart Association. The condition ...
... 11 (HealthDay News) -- Many U.S. hospitals don,t follow ... angioplasty and stenting in patients who have a blocked ... finds. A U.S. National Heart, Lung, and Blood ... Trial (OAT), found that angioplasty and stenting -- known ...
Cached Medicine News:Health News:Contact Allergies Associated With Lower Rates of Some Cancers 2Health News:Pitt team finds way to classify post-cardiac arrest patients to better predict outcomes 2Health News:Sleep Apnea Linked to Blood Vessel Disorders in Study 2Health News:Adherence to Angioplasty/Stent Guidelines Lacking: Study 2Health News:Adherence to Angioplasty/Stent Guidelines Lacking: Study 3
... Hycor Biomedical Ltd Autostat™II Rheumatoid Factor IgM ... Rheumatoid Factor IgM (RF IgM). Enzyme-linked immunosorbent ... specific IgM Rheumatoid Factor in human serum. ... can be used as an aid in ...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
... Scheimpflug Analyzer is a high precision optical ... analysis of the anterior eye segment, based ... and a Placido Disk. , GALILEI combines ... furnishes high accuracy curvature data, while Scheimpflug ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: